Designing new drug combinations to fight resistant infections and emerging pathogens
Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens
This study is working on new ways to combine medications to better treat tough infections, like those from HIV and tuberculosis, so that patients can get personalized treatments that fit their specific health needs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10596722 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drug combinations to effectively treat infections caused by resistant and emerging pathogens, including those related to HIV and tuberculosis. The project aims to establish a new laboratory dedicated to creating personalized treatment regimens that can adapt to the unique characteristics of various pathogens. By leveraging a network of clinical data and advanced methodologies, the research seeks to enhance our ability to combat infections that are increasingly difficult to treat. Patients may benefit from tailored therapies that are specifically designed to address their individual health needs.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with infections caused by multiple drug-resistant pathogens or those at risk of emerging infectious diseases.
Not a fit: Patients with infections that are easily treatable with existing therapies may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from infections caused by resistant pathogens.
How similar studies have performed: Other research has shown promise in developing combination therapies for resistant infections, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Hu, Linden T — Tufts University Boston
- Study coordinator: Hu, Linden T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.